There was no higher risk of heart attack for recipients of the two-dose hepatitis B cytosine phosphoguanine adjuvant vaccine (Heplisav-B) compared to the three-dose hepatitis B vaccine with an ...
A prospective, observational cohort study at Kaiser Permanente Southern California was conducted in which 31,183 adults received at least one dose of HepB-CpG vaccine (Heplisav-B, 2-dose) and 38,442 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback